Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib in HER2 Positive Refractory or Metastatic Gastrointestinal Tumors
NCT04960943Phase 2Unknown
- Sponsor
- Fudan University
- Start
- Feb 2020
- Primary completion
- Sep 2022
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of pyrotinib in gastrointestinal tumor, gastric cancer (GC), esophageal adenocarcinoma (EAC), colorectal cancer (CRC), sponsored by Fudan University. Status: unknown.
02
Drugs
pyrotinib
03
Conditions
gastrointestinal tumorgastric cancer (GC)esophageal adenocarcinoma (EAC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04960943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04960943.